罗格列酮对2型糖尿病心血管相关标志物的影响

目的：观察2型糖尿病的一些心血管相关标志物水平变化及罗格列酮（RSC）对这些标志物的影响。方法：157例受试者分为正常对照组（NGT）、糖耐量低减组（IGT）、2型糖尿病未合并大血管病变组（DM。）及合并大血管病变组（DM2）。应用RSG（4mg／d）治疗16周后，观察c反应蛋白（CRP）、Ⅰ型血浆纤溶酶原活化抑制剂（PAI-1）、假性血友病因子（vWF）、基质金属蛋白酶-9（MMP-9）的水平变化。结果：治疗前从NGT、IGT、DM，副DM2组，CRP、PAI-1、vWF、MMP-9水平逐渐升高，CRP、PAI-1在各组间有显著差异（P〈0．05）；DM1、DM2组vWF和MMP-9与NGT、IGT组比较有显著差异（P〈0．05）；经RSG治疗后，IGT组、DM1组CRP水平明显下降（P〈0．01），各组PAI-1下降（P〈0．01），DM2组vWF和MMP-9下降（P〈0．05）。结论：RSG不同程度降低心血管相关标志物水平，对IGT和2型糖尿病心血管具有保护作用。

Effects of rosiglitazone on markers for cardiovascular disease in type 2 diabetes mellitus

Objective: To investigate the levels of markers for cardiovascular disease in type 2 diabetes mellitus and the effect of rosiglitazone(RSG) on these markers.Methods:This study included 43 healthy subjects(NGT group),40 patients with impaired glucose tolerance(IGT group),and 74 patients with type 2 diabetes mellitus(T2DM).The patients with T2DM were further divided into T2DM without(DM_1 group,32 patients) and with(DM_2 group,42 patients) macrovascular complication.The markers for cardiovascular disease including serum C-reactive protein(CRP),plasminogen activator inhibitor type-1(PAI-1),von Willebrand factor(vWF),and serum matrix metalloproteinase-9(MMP-9) were detected 16 weeks after the patients being treated with RSG(4 mg/d).Results:The levels of CRP,PAI-1,vWF and MMP9 in NGT,IGT,DM_1,and DM_2 groups gradually increased in sequence.There were significant differences in the levels of CRP and PAI-1 between any 2 of these 4 groups(P<0.05).The levels of vWF and MMP-9 in DM_1 and DM_2 groups were significantly higher than those in NGT and IGT groups.The level of CRP in IGT and DM_1 groups,the level of PAI-1 in each group,and the levels of vWF and MMP-9 in DM_2 group after the admininstration of RSG were significantly lower than those before the administration(P<0.01).Conclusion:Some markers for cardiovascular diseases significantly increase in patients with IGT and T2DM,and RSG could effectively inhibit the increase of these markers and thus have a protective effect on macrovascular diseases.